Elevation of plasma glucagon-like immunoreactivity (GLI) in patients with liver cirrhosis. 1986

A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima

Plasma glucagon-like immunoreactivity (GLI) levels were increased in patients with liver cirrhosis. The levels were not significantly correlated with plasma glucagon immunoreactivity (GI) and serum insulin levels. None of the conventional liver function tests were correlated with the GLI levels, although plasma GI levels were high in cirrhotics with hyperammonemia. A significant correlation between plasma GLI and amino acid levels was not observed in these cases. The oral glucose tolerance test (OGTT) showed a significant decrease of plasma GI levels in cirrhotics but no change of plasma GLI concentrations: cirrhotic patients with diabetes mellitus or total gastrectomy showed marked increases of GLI levels. Glucagon (Glucagon Novo) injection at a dose of 10 micrograms/kg body weight to cirrhotic patients produced marked increases of both GI and GLI levels rapidly, though the mechanism of GLI elevation could not be clearly explained.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D004763 Glucagon-Like Peptides Peptides derived from proglucagon which is also the precursor of pancreatic GLUCAGON. Despite expression of proglucagon in multiple tissues, the major production site of glucagon-like peptides (GLPs) is the INTESTINAL L CELLS. GLPs include glucagon-like peptide 1, glucagon-like peptide 2, and the various truncated forms. Enteroglucagon,Enteroglucagons,Glucagon-Like Peptide,Glucagon-Like Polypeptide,Gut Glucagon,Glucagon-Like Polypeptides,Glucagon Like Peptide,Glucagon Like Peptides,Glucagon Like Polypeptide,Glucagon Like Polypeptides,Glucagon, Gut,Peptide, Glucagon-Like,Polypeptide, Glucagon-Like
D005260 Female Females
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
April 1975, The Tohoku journal of experimental medicine,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
September 1970, Diabetes,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
September 1970, Diabetes,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
January 1981, Zeitschrift fur Naturforschung. Section C, Biosciences,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
April 1986, Indian journal of biochemistry & biophysics,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
June 1981, Endocrinologia japonica,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
January 1973, The Journal of clinical endocrinology and metabolism,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
December 1982, Horumon to rinsho. Clinical endocrinology,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
January 1992, Life sciences,
A Watanabe, and M Hashimoto, and T Higashi, and M Kobayashi, and H Nakatsukasa, and Y Yamauchi, and M Watanabe, and M Fujiwara, and H Nagashima
May 1979, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Copied contents to your clipboard!